The financing provides $100 million in committed capital, intended to fund the Company through clinical trial initiation of its oral small molecule GLP-1. The financing was co-led by new investors Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital. Existing investors BVF Partners and Boulder Ventures also participated, and were joined by additional new investors Janus Henderson Investors, Samsara BioCapital, and an undisclosed institutional investor.